Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML
Open Access
- 6 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 31 (5), 2944-2955
- https://doi.org/10.1007/s00330-020-07362-y
Abstract
Objectives To compare brain MRI findings in progressive multifocal leukoencephalopathy (PML) associated to rituximab and natalizumab treatments and HIV infection. Materials and methods In this retrospective, multicentric study, we analyzed brain MRI exams from 72 patients diagnosed with definite PML: 32 after natalizumab treatment, 20 after rituximab treatment, and 20 HIV patients. We compared T2- or FLAIR-weighted images, diffusion-weighted images, T2*-weighted images, and contrast enhancement features, as well as lesion distribution, especially gray matter involvement. Results The three PML entities affect U-fibers associated with low signal intensities on T2*-weighted sequences. Natalizumab-associated PML showed a punctuate microcystic appearance in or in the vicinity of the main PML lesions, a potential involvement of the cortex, and contrast enhancement. HIV and rituximab-associated PML showed only mild contrast enhancement, punctuate appearance, and cortical involvement. The CD4/CD8 ratio showed a trend to be higher in the natalizumab group, possibly mirroring a more efficient immune response. Conclusion Imaging features of rituximab-associated PML are different from those of natalizumab-associated PML and are closer to those observed in HIV-associated PML. Key Points • Nowadays, PML is emerging as a complication of new effective therapies based on monoclonal antibodies. • Natalizumab-associated PML shows more inflammatory signs, a perivascular distribution “the milky way,” and more cortex involvement than rituximab- and HIV-associated PML. • MRI differences are probably related to higher levels of immunosuppression in HIV patients and those under rituximab therapy.This publication has 27 references indexed in Scilit:
- Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRISJournal of Neurology, Neurosurgery & Psychiatry, 2017
- Progressive Multifocal Leukoencephalopathy and Monoclonal AntibodiesCancer Control, 2017
- Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature ReviewFrontiers in Immunology, 2017
- Progressive multi-focal leucoencephalopathy – driven from rarity to clinical mainstream by iatrogenic immunodeficiencyClinical and Experimental Immunology, 2017
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupJournal of Neurology, Neurosurgery & Psychiatry, 2015
- Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated EntitiesMultiple Sclerosis International, 2015
- Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS)Acta Neuropathologica, 2015
- The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathyMultiple Sclerosis Journal, 2013
- Magnetic resonance imaging pattern in natalizumab‐associated progressive multifocal leukoencephalopathyAnnals of Neurology, 2012
- Imaging manifestations of progressive multifocal leukoencephalopathyClinical Radiology, 2010